Boehringer Ingelheim prides itself on the high standards of broad-ranging, educational materials it provides for the global community at large, and strives to amalgamate up-to-date didactic and accurate information with the constantly changing tools modern media supplies.
Dedicated to cancer research, Boehringer Ingelheim has more than 400 employees around the world who are actively involved in the discovery and development of both biopharmaceuticals and small-molecule drugs as breakthrough agents for combating cancer.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. As a research-driven company, Boehringer Ingelheim is committed to discovering and developing new products of high therapeutic value for patients, physicians and other healthcare providers.
With front-line research and development projects, Boehringer Ingelheim has embarked on a major drive to the emergence of new cancer drugs. We aim to bridge therapeutic gaps with innovative treatments to improve health and enhance the quality of life of cancer patients.
Provide patients and oncologists with first-in-class treatment options or exceed the therapeutic outcomes of existing treatments in terms of efficacy, tolerability or convenience. Boehringer Ingelheim endeavours to combine groundbreaking science with high therapeutic value for patients, physicians and healthcare providers.
Boehringer Ingelheim GmbH
Corporate Division Communications
Binger Strasse 173
55216 Ingelheim am Rhein
Phone +49 / 6132 / 77 0
Fax +49 / 6132 / 72 0